A phase 2, multicenter study of FOLFIRINOX followed by ipilimumab in combination with allogeneic GM-CSF transfected pancreatic tumor vaccine in the treatment of metastatic pancreatic cancer.

Patel, Rina K.; Ko, Andrew H.; Onners, Beth; Uram, Jennifer N.; Parkinson, Rose; Sugar, Elizabeth A.; Li, Zheng; Laheru, Daniel A.; Jaffee, Elizabeth M.; Le, Dung T.

doi:10.1200/jco.2014.32.15_suppl.tps4160

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results have received certain interest in perspective, hence LAG-3 will be considered as the promising targeted immunotherapy and predictive biomarker 174 . Table 1 9 , 120 , 121 , 122 , 123 , 127 , 129 , 134 , 135 , 136 , 137 , 138 , 139 , 142 , 143 , 144 , 145 , 146 , 149 , 150 , 151 , 152 , 153 , 166 , 175 , 176 summarizes the clinical trials of targeted ICPs in PCa.…”

Section: Targeting Immune Checkpointsmentioning

confidence: 99%

“… Target Drug Phase Status Clinical Trials identiﬁer Ref. CTLA-4 Ipilimumab II Completed NCT00112580 120 Ipilimumab ± GVAX I Completed NCT00836407 121 Ipilimumab + GVAX II Recruiting NCT01896869 175 Ipilimumab + gemcitabine Ib Completed NCT01473940 122 Ipilimumab + nivolumab with radiation II Recruiting NCT03104439 123 Tremelimumab (CP-675,206) + gemcitabine Ib Completed NCT00556023 128 Tremelimumab + durvalumab II Completed NCT02558894 127 PD-1 Pembrolizumab + REOLYSIN + chemotherapy II Recruiting NCT02620423 137 Pembrolizumab + ACP-196 II Active but not recruiting NCT02362048 136 Pembrolizumab (MK3475) I/II Recruiting NCT02305186 135 Pembrolizumab + PLX3397 I Recruiting NCT02452424 134 Pembrolizumab + oncolytic virus pelareorep Ib Recruiting NCT02620423 138 Pembrolizumab + PEGPH20 II Recruiting NCT03634332 …”

Section: Targeting Immune Checkpointsmentioning

confidence: 99%

See 1 more Smart Citation

Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development

Kiaie

Sanaei

Heshmati

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Immunotherapy has been recently considered as a promising alternative for cancer treatment. Indeed, targeting of immune checkpoint (ICP) strategies have shown significant success in human malignancies. However, despite remarkable success of cancer immunotherapy in pancreatic cancer (PCa), many of the developed immunotherapy methods show poor therapeutic outcomes in PCa with no or few effective treatment options thus far. In this process, immunosuppression in the tumor microenvironment (TME) is found to be the main obstacle to the effectiveness of antitumor immune response induced by an immunotherapy method. In this paper, the latest findings on the ICPs, which mediate immunosuppression in the TME have been reviewed. In addition, different approaches for targeting ICPs in the TME of PCa have been discussed. This review has also synopsized the cutting-edge advances in the latest studies to clinical applications of ICP-targeted therapy in PCa.

show abstract